Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Alberta T2N 4N1, Canada.
Eur J Neurosci. 2010 Mar;31(6):994-1005. doi: 10.1111/j.1460-9568.2010.07129.x. Epub 2010 Mar 8.
Current treatment regimes for a variety of mental disorders involve various selective serotonin reuptake inhibitors such as Fluoxetine (Prozac). Although these drugs may 'manage' the patient better, there has not been a significant change in the treatment paradigm over the years and neither have the outcomes improved. There is also considerable debate as to the effectiveness of various selective serotonin reuptake inhibitors and their potential side-effects on neuronal architecture and function. In this study, using mammalian cortical neurons, a dorsal root ganglia cell line (F11 cells) and identified Lymnaea stagnalis neurons, we provide the first direct and unequivocal evidence that clinically relevant concentrations of Fluoxetine induce growth cone collapse and neurite retraction of both serotonergic and non-serotonergic neurons alike in a dose-dependent manner. Using intracellular recordings and calcium imaging techniques, we further demonstrate that the mechanism underlying Fluoxetine-induced effects on neurite retraction from Lymnaea neurons may involve lowering of intracellular calcium and a subsequent retardation of growth cone cytoskeleton. Using soma-soma synapses between identified presynaptic and postsynaptic Lymnaea neurons, we provide further direct evidence that clinically used concentrations of Fluoxetine also block synaptic transmission and synapse formation between cholinergic neurons. Our study raises alarms over potentially devastating side-effects of this antidepressant drug on neurite outgrowth and synapse formation in a developing/regenerating brain. Our data also demonstrate that drugs such as Fluoxetine may not just affect communication between serotonergic neurons but that the detrimental effects are widespread and involve neurons of various phenotypes from both vertebrate and invertebrate species.
目前,各种精神障碍的治疗方案都涉及到各种选择性 5-羟色胺再摄取抑制剂,如氟西汀(百忧解)。尽管这些药物可能会“更好地”治疗患者,但多年来治疗模式并没有显著改变,治疗效果也没有改善。此外,各种选择性 5-羟色胺再摄取抑制剂的有效性及其对神经元结构和功能的潜在副作用也存在相当大的争议。在这项研究中,我们使用哺乳动物皮质神经元、背根神经节细胞系(F11 细胞)和鉴定的田螺神经元,首次直接且明确地证明了临床相关浓度的氟西汀以剂量依赖的方式诱导 5-羟色胺能和非 5-羟色胺能神经元的生长锥塌陷和轴突回缩。通过细胞内记录和钙成像技术,我们进一步证明了氟西汀诱导田螺神经元轴突回缩的机制可能涉及降低细胞内钙,随后生长锥细胞骨架的延迟。通过鉴定的田螺神经元之间的胞体-胞体突触,我们提供了进一步的直接证据,表明临床使用浓度的氟西汀也会阻断胆碱能神经元之间的突触传递和突触形成。我们的研究对这种抗抑郁药在发育/再生大脑中的神经元突起生长和突触形成方面可能产生的潜在破坏性副作用发出了警报。我们的数据还表明,氟西汀等药物可能不仅会影响 5-羟色胺能神经元之间的通讯,而且这种有害影响还广泛存在,涉及来自脊椎动物和无脊椎动物的各种表型的神经元。